ATED Therapeutics is a Tel Aviv, Israel and Greenwich, Ct. based biotechnology company focused on developing BOTH a new diagnostic test, and therapeutic drugs for Parkinson's disease (PD). We are raising up to $1M in a Seed round.
PD is the second most prevalent ( after Alzheimer's disease) and fastest growing neurodegenerative disease (CAGR 11.3%). There are up to 1 million cases in the U.S., 1.2 M in the EU. and 5M+ in China. These numbers are expected to double by 2030. 20%-25% of patients are initially misdiagnosed. By the time PD is diagnosed 50%-70% of the dopaminergic neurons in the brain (substantia nigra pars compacta ) are already destroyed. Early and accurate diagnosis is crucial to treating PD effectively and extending the life span of patients.
Working with Hebrew University in Jerusalem we have exclusive rights to the first blood based diagnostic test for PD. This test is based on measuring tRNA from nucleated red blood cells. Results come back in one day using qPCR. Sensitivity and specificity are as high if not better than what has been shown with the SYNTap CSF test.
You may have read that Amprion has developed a diagnostic test for PD by measuring alpha-synuclein in cerebral spinal fluid (CSF). This test requires a risky spinal tap procedure with attendant side effects and results come back in 15 days. Cost for the spinal tap alone is $3K-$5K. The cost of the test is $1500/test. Our blood test may well cost 10X less.
A blood test is faster, more accurate, cost less, and easier to obtain a sample. The test can detect PD early in the course of the disease (prodromal stage) 2) monitor progression and extent of disease, 3) avoid misdiagnosis of PD and 4) in time, become a standard screening blood test for all patients over age 65 (population screening for PD was just discussed at the 6th World Parkinson Conf.in Barcelona). We hope to file with the FDA in late Q4 or early Q12024.
In addition, working with Hebrew University we are developing two new drugs to treat PD, SuperDopamide (SD) and SuperDopa (SDA, see attached ppt.). SDA: 1) reduces oxidative stress in neurons preventing apoptosis and 2) prevents alpha-synuclein aggregation, and 3) may reverse alpha-syn oligomerization suggesting the possibility that it may slow or halt progression of the disease. These drugs are a combination of levodopa and N-acetylcysteine. Both drugs should be ready for clinical trials in 2024.
Ready to Ask For Funding for your company?
Post a Funding Request